Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
Recruiting
Nippon Shinyaku Co., Ltd.
Phase 3
2020-04-14
The main objective of this study is to evaluate the efficacy of Viltolarsen compared to
placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
Recruiting
NS Pharma, Inc.
Phase 3
2020-04-14
The main objective of this study is to evaluate the efficacy of Viltolarsen compared to
placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
Recruiting
NS Pharma, Inc.
Phase 4
2021-06-10
The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial
(Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD
who complete the NS-065/NCNP-01-202 study.
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
Recruiting
Nippon Shinyaku Co., Ltd.
Phase 3
2021-04-13
This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who
have completed the 48-week treatment period of either viltolarsen or placebo in Study
NS-065/NCNP-01-301.
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
Recruiting
NS Pharma, Inc.
Phase 3
2021-04-13
This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who
have completed the 48-week treatment period of either viltolarsen or placebo in Study
NS-065/NCNP-01-301.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
